151 related articles for article (PubMed ID: 17537213)
1. Long-term effects of a short course of neoadjuvant luteinizing hormone-releasing hormone analogue and radical radiotherapy on the hormonal profile in patients with localized prostate cancer.
Murthy V; Norman AR; Barbachano Y; Parker CC; Dearnaley DP
BJU Int; 2007 Jun; 99(6):1380-2. PubMed ID: 17537213
[TBL] [Abstract][Full Text] [Related]
2. Recovery of serum testosterone, LH and FSH levels following neoadjuvant hormone cytoreduction and radical radiotherapy in localized prostate cancer.
Shahidi M; Norman AR; Gadd J; Huddart RA; Horwich A; Dearnaley DP
Clin Oncol (R Coll Radiol); 2001; 13(4):291-5. PubMed ID: 11554629
[TBL] [Abstract][Full Text] [Related]
3. Recovery of serum testosterone after neoadjuvant androgen deprivation therapy and radical radiotherapy in localized prostate cancer.
Murthy V; Norman AR; Shahidi M; Parker CC; Horwich A; Huddart RA; Bange A; Dearnaley DP
BJU Int; 2006 Mar; 97(3):476-9. PubMed ID: 16469011
[TBL] [Abstract][Full Text] [Related]
4. Recovery of Serum Testosterone Levels and Sexual Function in Patients Treated With Short-term Luteinizing Hormone-releasing Hormone Antagonist as a Neoadjuvant Therapy Before External Radiotherapy for Intermediate-risk Prostate Cancer: Preliminary Prospective Study.
Inoue T; Mizowaki T; Kabata D; Shintani A; Terada N; Yamasaki T; Negoro H; Kobayashi T; Nakamura K; Inokuchi H; Ogawa O
Clin Genitourin Cancer; 2018 Apr; 16(2):135-141.e1. PubMed ID: 29051056
[TBL] [Abstract][Full Text] [Related]
5. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
Hall MC; Fritzsch RJ; Sagalowsky AI; Ahrens A; Petty B; Roehrborn CG
Urology; 1999 May; 53(5):898-902; discussion 902-3. PubMed ID: 10223480
[TBL] [Abstract][Full Text] [Related]
6. Germinal cell aplasia: response of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone to LH/FSH-releasing hormone with histopathologic correlation.
Guay AT; Tuthill RJ; Woolf PD
Fertil Steril; 1977 Jun; 28(6):642-9. PubMed ID: 324822
[TBL] [Abstract][Full Text] [Related]
7. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
8. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
Behre HM; Baus S; Kliesch S; Keck C; Simoni M; Nieschlag E
J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
[TBL] [Abstract][Full Text] [Related]
9. Follicle-stimulating hormone promotes growth of human prostate cancer cell line-derived tumor xenografts.
Oduwole OO; Poliandri A; Okolo A; Rawson P; Doroszko M; Chrusciel M; Rahman NA; Serrano de Almeida G; Bevan CL; Koechling W; Huhtaniemi IT
FASEB J; 2021 Apr; 35(4):e21464. PubMed ID: 33724574
[TBL] [Abstract][Full Text] [Related]
10. Contrasts in the gonadotropin-releasing hormone dose-response relationships for luteinizing hormone, follicle-stimulating hormone and alpha-subunit release in young versus older men: appraisal with high-specificity immunoradiometric assay and deconvolution analysis.
Zwart AD; Urban RJ; Odell WD; Veldhuis JD
Eur J Endocrinol; 1996 Oct; 135(4):399-406. PubMed ID: 8921820
[TBL] [Abstract][Full Text] [Related]
11. Testosterone and erectile function recovery after radiotherapy and long-term androgen deprivation with luteinizing hormone-releasing hormone agonists.
Wilke DR; Parker C; Andonowski A; Tsuji D; Catton C; Gospodarowicz M; Warde P
BJU Int; 2006 May; 97(5):963-8. PubMed ID: 16542340
[TBL] [Abstract][Full Text] [Related]
12. [Serum testosterone, dihydrotestosterone, luteinizing hormone and follicle-stimulating hormone versus prostate specific antigen in patients with localized prostate adenocarcinoma who underwent radical prostatectomy. Radioimmunoassays measurements].
Bantis A; Zissimopoulos A; Athanasiadou P; Gonidi M; Agelonidou E; Strataki A; Matthaios D; Tsartsarakis A
Hell J Nucl Med; 2007; 10(1):56-61. PubMed ID: 17450256
[TBL] [Abstract][Full Text] [Related]
13. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
Kaku H; Saika T; Tsushima T; Ebara S; Senoh T; Yamato T; Nasu Y; Kumon H
Prostate; 2006 Mar; 66(4):439-44. PubMed ID: 16329145
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant hormone therapy for radical prostate radiotherapy: bicalutamide monotherapy vs. luteinizing hormone-releasing hormone agonist monotherapy: a single-institution matched-pair analysis.
McGivern U; Mitchell DM; McDowell C; O'Hare J; Corey G; O'Sullivan JM
Clin Genitourin Cancer; 2012 Sep; 10(3):190-5. PubMed ID: 22677511
[TBL] [Abstract][Full Text] [Related]
15. Effects of gonadotropin-releasing hormone pulse-frequency modulation on luteinizing hormone, follicle-stimulating hormone and testosterone secretion in hypothalamo/pituitary-disconnected rams.
Wu FC; Irby DC; Clarke IJ; Cummins JT; de Kretser DM
Biol Reprod; 1987 Oct; 37(3):501-10. PubMed ID: 3118979
[TBL] [Abstract][Full Text] [Related]
16. Hormonal pattern and testicular histology in patients with prostatic cancer after long-term treatment with a gonadotropin-releasing hormone agonist analogue.
Giberti C; Barreca T; Martorana G; Truini M; Franceschini R; Rolandi E; Giuliani L
Eur Urol; 1988; 15(1-2):125-7. PubMed ID: 2975220
[TBL] [Abstract][Full Text] [Related]
17. Gonadotropin and steroid secretory patterns during chronic treatment with a luteinizing hormone-releasing hormone agonist analog in men.
Evans RM; Doelle GC; Alexander AN; Uderman HD; Rabin D
J Clin Endocrinol Metab; 1984 May; 58(5):862-7. PubMed ID: 6423661
[TBL] [Abstract][Full Text] [Related]
18. Aromatization mediates testosterone's short-term feedback restraint of 24-hour endogenously driven and acute exogenous gonadotropin-releasing hormone-stimulated luteinizing hormone and follicle-stimulating hormone secretion in young men.
Schnorr JA; Bray MJ; Veldhuis JD
J Clin Endocrinol Metab; 2001 Jun; 86(6):2600-6. PubMed ID: 11397860
[TBL] [Abstract][Full Text] [Related]
19. Effect of an anabolic steroid (metandienon) on plasma LH-FSH, and testosterone and on the response to intravenous administration of LRH.
Holma P; Adlercreutz H
Acta Endocrinol (Copenh); 1976 Dec; 83(4):856-64. PubMed ID: 793272
[TBL] [Abstract][Full Text] [Related]
20. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production.
Matsumoto AM
J Clin Endocrinol Metab; 1990 Jan; 70(1):282-7. PubMed ID: 2104626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
